Biovertis AG
This article was originally published in Start Up
Executive Summary
Intercell AG spin-out Biovertis AG aims to leverage its parent company's vaccine antigen discovery platform to pinpoint novel targets for anti-infective drugs. Vienna-based Biovertis employs a structure-based drug discovery program; a recent Series A should fund the company into 2007.